Kornimate/medical-research-clean huggingface dataset:
interventions to increase hbv vaccinations in sexually transmitted disease (std) clinics

Conditions: Hepatitis B Virus

Summary: the goal of this study is to evaluate two sets of interventions to increase acceptance of hepatitis b virus (hbv) vaccination in patients attending sexually transmitted disease (std) clinics. the 1st set of interventions, with 3 levels, is based on message framing. the 3 levels are: 1. information only; 2. gain-framed message; and 3. loss-framed message. the 2nd set of interventions, with 2 levels, involves how the vaccine is recommended by the health care provider. the 2 levels are: 1. hbv vaccine offered; and 2. hbv vaccine recommended. the outcome of interest is1st dose acceptance.

the goal of this study is to evaluate two sets of interventions to increase acceptance of hepatitis b virus (hbv) vaccination in patients attending sexually transmitted disease (std) clinics. the 1st specific aim is to assess the effect of message-framing on vaccine acceptance. framing theory suggests that positively framed messages (i.e., benefits of getting vaccine) are more effective than negatively framed messages (i.e., dangers of not getting vaccine) in stimulating preventive health behaviors. research on framing theory and engagement in health behaviors suggests also that the effects may be moderated by other attitudinal factors, including perceived risk of the behavior and degree of involvement in the message. the 2nd aim is to evaluate the effect of provider-based interventions. prior research suggests that recommendations by health providers are very important in patients' decisions regarding acceptance of health care procedures. patients (18 years and older) will be recruited and followed from chicago and indianapolis std clinics during routine medical visits. an audio computer-assisted self-interview (a-casi) will cover demographics, risk behaviors, and perceived risk associated with vaccination. subjects then will be randomized to receive a gain-framed, loss-framed, or information only message regarding hbv immunization (also delivered by a-casi). upon completion of the message-framing intervention, subjects will complete additional attitude questions via a-casi. upon completion of the a-casi subjects will be randomly assigned to one of two provider intervention conditions: 1. vaccine offered or 2. vaccine recommended. for both conditions free hbv immunization will be provided by a nurse practitioner. subsequently, postcard reminders will be sent and phone call reminders made for follow-up appointments for those receiving the first and second doses of vaccine. the primary outcome measure is hbv vaccination.

Eligibility criteria:
inclusion criteria: * age 18 and older males and females * no prior self-reported history of hbv immunization or infection * fluent in english * not known to be hiv positive. exclusion criteria: * under age 18 * received any prior hbv vaccination * prior infection of hepatitis b * unable to read or comprehend the english language * hiv positive

Keywords: attitude to health communication intervention studies health promotion psychology, medical sexual behavior behavioral research vaccination
middle school teacher module for a brief bullying intervention program

Conditions: Bullying

Summary: this study evaluates the feasibility and short-term outcomes of a teacher training designed as a companion module to a bullying bystander intervention (stac) for middle school students in rural communities. the aim of this project is to provide a brief, low-cost intervention that can be easily disseminated as part of a school-based bullying prevention program to address this important public health problem.


Eligibility criteria:
inclusion criteria: * being a teacher of an adolescent enrolled in grades 6, 7, or 8 in a participating middle school in idaho. * speaks and reads english. * consents to participate. exclusion criteria: * speaks and reads only a language other than english. * does not consent for participation.
effectiveness of tap (transversus abdominis plane) block for abdominal aortic surgery

Conditions: Abdominal Aortic Aneurysm; Abdominal Aortic Stenosis; Syndrome, Leriche

Summary: the goal of this study is to learn about the effectiveness of tap block for pain relief after vascular surgery on the abdominal aorta. the main question the investigators are looking to answer is whether the tap block lowers the dose of opioid required after abdominal aortic surgery.

the surgery on the abdominal aorta requires extended haemodynamic monitoring and is performed under general anaesthesia. after applying general anaesthesia, the patients will receive a tap block (subcostal approach) before the start of the surgery. during the procedure the patients will receive both opioid and nonopioid analgesics, as part of the standard perioperative protocol for abdominal aortic surgery. after the procedure all patients will receive following the standard protocol for pain relief after abdominal aortic surgery - nsaids and nonopioid analgesics regularly. all patients will postoperatively receive opioid as a rescue drug as needed (pca). participants will be randomly allocated in two groups, where one group will receive local anaesthetic for the tap block and the control group will receive normal saline for the tap block. the anaesthetist, the nurses and doctors in the postoperative care will all be blinded as to the group in which each patient is allocated. the participants will be followed from surgery until discharge from hospital.

Eligibility criteria:
inclusion criteria: * adult patients admitted for an elective vascular surgery on abdominal aorta that agree and give written consent to be included in the study. exclusion criteria: * patients allergic to the drugs we will use in the study, local anaesthetic, nonopioid analgesics, nsaids. * patients with pain syndromes that are preoperatively already on any kind of chronic pain therapy. * patients that will experience surgical complications that requires reoperation will be excluded postoperatively.

Keywords: abdominal aorta, tap
endotracheal intubation devices

Conditions: Intubation

Summary: the purpose of this study was to compare the four different intubation devices in 6 different scenarios.


Eligibility criteria:
inclusion criteria: * give voluntary consent to participate in the study * minimum 1 year of work experience in emergency medicine * experienced emergency medical personnel (paramedics, nurses, physicians) exclusion criteria: * not meet the above criteria * wrist or low back diseases
rosiglitazone (avandia) vs. placebo for androgen dependent prostate cancer

Conditions: Adenocarcinoma of the Prostate; Prostate Cancer

Summary: the purpose of this study it to learn the effects (good or bad) that rosiglitazone has on patients and their prostate cancer. this study is going to look at what effects rosiglitazone has on prostate specific antigen (psa) levels.

* patients will be randomly assigned to initial treatment with either rosiglitazone or placebo orally twice daily, every day as long as there is no disease progression or serious side effects. patients will be asked to complete a drug log to keep track of the medication. * before treatment begins the following tests will be performed: physical exam; bone scan; blood work (including psa level test) and a urine sample. * while on this study the following tests and procedures will be done once a month: review of side effects and routine blood tests (including psa levels). * while on this study the following tests and procedures will be done on months 2 and 4: review of side effects; routine blood tests (including psa levels) and urine tests. * if the patient's disease progressed the treatment code will be broken and if the patient was on placebo, they will have the option to begin taking rosiglitazone.

Eligibility criteria:
inclusion criteria: * histologically confirmed adenocarcinoma of the prostate * biochemical disease progression following local therapy defined as three rises in psa with each psa determination at least 4 weeks apart and each psa value \> or = 0.2ng/ml * for men treated with radical prostatectomy, psa \> or = 2 ng/ml * for men treated with primary radiation therapy or post-prostatectomy radiation therapy, psa \> or = 2 ng/ml and \> 150% post-radiation nadir * not an appropriate candidate for salvage radiation therapy or salvage prostatectomy * baseline psadt \< 24 months * calgb performance status of 0,1 or 2 exclusion criteria: * metastatic disease * prior hormonal therapy for recurrent prostate cancer * prior chemotherapy for prostate cancer * current treatment with insulin or an oral hypoglycemic * history of treatment with thiazolidinediones * radiation therapy within 6 months * sgot \> 1.5 x uln * fasting blood glucose \< 60 mg/dl * nyha class 3 or 4 cardiac status

Keywords: rosiglitazone avandia androgen dependant prostate cancer
study to assess the effect of tezepelumab on the immune response to influenza vaccination in participants with asthma

Conditions: Moderate to Severe Asthma

Summary: this is a phase 3b, multicenter, randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of tezepelumab (210 mg subcutaneous \[sc\] every 4 weeks \[q4w\]) on antibody responses following seasonal quadrivalent influenza virus vaccination in the fall/winter 2021-2022 in the usa.

participants with moderate to severe asthma will enter the screening period of a minimum of 2 weeks to allow adequate time for all of the eligibility criteria to be evaluated. they will be randomized 1:1 to receive tezepelumab 210 mg or placebo sc q4w, administered at weeks 0, 4, 8 and 12. randomization will be monitored to ensure at least 50% of the randomized participants are between the ages of 12 to 17 years. participants will receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at week 12, prior to the fourth dose of study intervention. serum samples for evaluation of antibody response will be drawn at week 12 (pre-vaccination) and at week 16 (4 weeks post-vaccination) when humoral response to the vaccination is expected to be fully developed. the end of treatment (eot) visit will be conducted at week 16 and a final follow-up visit and the end of study visit will be conducted at week 28.

Eligibility criteria:
inclusion criteria: * documented physician-diagnosed asthma for at least 12 months prior to visit 1. * morning pre-bronchodilator fev1 (forced expiratory volume) of \> 50% predicted normal value at visit 1 or visit 2. * body weight ≥ 40 kg. * for women of childbearing potential, a negative urine pregnancy test is required prior to administration of study intervention at visit 3. * must have 'not well-controlled' asthma. exclusion criteria: * clinically important pulmonary disease other than asthma. * any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment. * life-threatening asthma * history of cancer. * allergy to eggs, if egg based influenza vaccine will be administered. * history of anaphylaxis to any biologic therapy. * current smokers or participants with smoking history ≥ 10 pack-years and participants using vaping products, including electronic cigarettes. former smokers with a smoking history of \< 10 pack-years and users of vaping or e-cigarette products must have stopped for at least 6 months prior to visit 1 to be eligible. * history of alcohol or drug abuse within 12 months prior to the date of informed consent. * major surgery within 8 weeks prior to visit 1 or planned surgical procedures during the conduct of the study.

Keywords: tezepelumab humoral immune response quadrivalent influenza vaccination antibody response subcutaneous
topcon 3d oct-1000 optical coherence tomography system

Conditions: Retinal Disease; Glaucoma

Summary: the purpose of this clinical protocol is to perform a comparison of retinal and retinal nerve fiber layer (rnfl) thickness measurements between the topcon 3d-1000 and the identified predicate device. in addition, this protocol performs a comparison of the thickness measurement results from images collected and analyzed with the zeiss stratus oct to images collected with the zeiss stratus oct and imported into the topcon 3d oct-1000 stratusviewer for analysis.


Eligibility criteria:
retinal disease study no retinal disease: inclusion criteria: * male or female * between 18 and 80 years of age * either eye, but only one eye per subject will be enrolled * topcon image quality factor ≥ 45 or stratus signal strength ≥ 5. exclusion criteria: * any known ocular disease * any systemic disease that could result in ocular manifestations such as hypertension, diabetes, heart disease, etc. * topcon image quality factor ≤ 44 or stratus signal strength \< 5. retinal disease inclusion criteria: * male or female * between 18 and 80 years of age * either eye, but only one eye per subject will be enrolled * symptoms consistent with one of the following retinal diseases: diabetic macular edema, cystoid macular edema, epiretinal membrane, macular hole, wet amd and dry amd for which oct imaging is warranted. at lease one (1) case each of these diseases will be included in the study * a range of retinal thickness will be included * topcon image quality factor ≥ 45 or stratus signal strength ≥ 5. exclusion criteria: * presence of glaucoma * topcon image quality factor ≤ 44 or stratus signal strength \< 5.
barrett's esophagus - 315 - 3 way cross-over

Conditions: Barrett's Esophagus

Summary: this study looks the intragastric and intraesophageal ph in patients with documented barrett's esophagus whilst taking esomeprazole 40mg twice daily, esomeprazole 40mg three times daily, esomeprazole 20 mg three times daily.


Eligibility criteria:
inclusion criteria: * must have a previously established, biopsy-proven diagnosis of barrett's esophagus with segment length greater than 3cm, with no dysplasia or adenocarcinoma within the previous 12 months exclusion criteria: * a history of esophageal, gastric, or duodenal surgery, including anti-reflux surgery or endoscopic anti-reflux procedures, except for simple closure of a gastric or duodenal ulcer. * history of various gastrointestinal diseases - please see investigator for full list. * evidence of any malignant disease in the last 5 years, except minor superficial skin disease. * unstable diabetes mellitus. stable on a controlled diet, oral agents or insulin are acceptable.

Keywords: nexium barrett's esophagus
improve the survival rate of chinese children and adolescents with non-hodgkin's lymphoma

Conditions: Childhood Non-Hodgkin's Lymphoma

Summary: non-hodgkin's lymphoma is an aggressive malignance disease in children and adolescents. this study was designed to evaluate the efficacy and toxicity of the modified nhl-bfm-90 protocol in chinese children and adolescents with non-hodgkin's lymphoma.

non-hodgkin's lymphoma (nhl) in children and adolescents include burkitt's lymphoma (bl), diffuse large b cell lymphoma (dlbl), anaplastic large cell lymphoma (alcl) and lymphoblastic lymphoma (lbl). these subtypes of nhl are an aggressive group of diseases. at present, in developed countries, 80 to 90% of children with nhl are cured by intensive, risk-adapted chemotherapy.the best protocols include bfm-90, lmb-89 and fab/lmb/96. however, in developing countries, such as those with low and moderate incomes, the limited availability of resources is an obstacle for using these complicated and intensive protocols.as such, very simple protocols, such as the chop protocol, were often used to treat children and adolescents with nhl, thus resulting in poor survival rates. to improve the survival rate of chinese children and adolescents with nhl, this study was designed to evaluate the efficacy and toxicity of this modified nhl-bfm -90 protocol in chinese children and adolescents with nhl.

Eligibility criteria:
inclusion criteria: 1. untreated children and adolescents with non-hodgkin's lymphoma 2. age ≤ 20 years 3. the informed consent of their guardians was obtained. exclusion criteria: 1. recurrence non-hodgkin's lymphoma 2. age \>20 years 3. no abide by the protocol

Keywords: non-hodgkin's lymphoma; childhood and adolescence; survival rate
correlation between missing posterior teeth and vertical dimension measurements with temporomandibular joint disorders in a sample of adult egyptian subjects

Conditions: Correlation Between Missing Posterior Teeth and Vertical Dimension Cephalometric Measurements With Temporomandibular Disorders

Summary: the goal of this observational study is to learn about the correlation between missing posterior teeth and vertical dimension cephalometric measurements with temporomandibular disorders in a sample of adult egyptian subjects in. the main questions it aims to answer are: * is there a correlation between missing posterior teeth and temporomandibular disorders? * is there a correlation between vertical dimension cephalometric measurements and temporomandibular disorders? participants will be asked for the following:- * to give their phone numbers \& it will be collected through the orthodontic department patient's database ensuring complete confidentiality. * to fill personal data chart (name, age, date of birth, mobile number, address). * to receive clinical examination to determine number of missing teeth. * to receive clinical examination to diagnose tmd using the dc/tmd. * to do lateral cephalometric radiograph to measure the vertical dimension.


Eligibility criteria:
inclusion criteria: * male and female patients with 2 or more missing posterior teeth seeking treatment at the faculty. * age: 16-49 years. exclusion criteria: * - patients who refuse to participate in the study. * patients younger than 16 years. * subjects who received previous tmd treatment. * subjects suffering from systemic conditions which may affect the functioning of tmj, for example, rheumatoid arthritis, scleroderma, and septic arthritis. * subjects with a history of trauma to the maxillofacial area. * subjects with a previous history of maxillofacial surgery. * subjects with a history of malignancy or current malignancy of the maxillofacial area.
ttx-030 in combination with immunotherapy and/or chemotherapy in subjects with advanced cancers

Conditions: Solid Tumor, Adult

Summary: this is a phase 1/1b study of ttx-030 in combination therapy, an antibody that inhibits cd39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (atp) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. this trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of ttx-030 in combination with immunotherapy and/or standard chemotherapies.


Eligibility criteria:
abbreviated inclusion criteria: 1. age 18 years or older, is willing and able to provide informed consent 2. histologically confirmed diagnosis of unresectable or metastatic solid tumor malignancy in selected tumor types 3. life expectancy \> 12 weeks 4. ecog performance status of 0-1 abbreviated exclusion criteria: 1. history of allergy or hypersensitivity to study treatment components. patients with a history of severe hypersensitivity reaction to any monoclonal antibody. 2. use of investigational agent within 28 days prior to the first dose of study treatment and throughout the study 3. receiving high-dose systemic steroid therapy or any other form of immunosuppressive therapy 4. history of severe autoimmune disease 5. uncontrolled intercurrent illness or other active malignancy requiring ongoing treatment

Keywords: gastric (gastroesophageal cancer) advanced solid tumor colorectal cancer cancer metastatic solid tumor combination therapy cd39 adenosine pathway immunotherapy immuno-oncology pd-1 checkpoint inhibitor docetaxel budigalimab abbv-181 ttx-030 non-small cell lung cancer urothelial cell cancer pancreatic cancer pembrolizumab keytruda bladder cancer gemcitabine nab-paclitaxel
dynamic changes of circulating tumor dna in late stage nsclc patients

Conditions: Carcinoma, Non-Small-Cell Lung; Bronchial Neoplasms; Carcinoma, Bronchogenic; Lung Diseases; Lung Neoplasms

Summary: a multi-centre observational, non-interventional study is to dynamically monitor the changes of circulating tumor dna (ctdna) in late stage nsclc patients under gefitinib treatment.


Eligibility criteria:
inclusion criteria: * provision of informed consent * histologically confirmed stage iiib/iv nsclc. * activating egfr mutations (g719a/c/s; exon 19 insertion/deletion; l858r; l861q) * able to comply with the required protocol and followed-up procedures, and able to receive oral medications exclusion criteria: * histologically confirmed small cell lung cancer or other metastatic tumors * patient had received prior chemotherapy or egfr-tkis treatment * patients who harbor exon20 t790m mutation

Keywords: circulating tumor dna lung cancer plasma dna
comparison of topical versus intravenous tranexamic acid in tka

Conditions: Total Blood Loss

Summary: previous studies in both the cardiovascular and orthopedic study have shown tranexamic acid (txa) reduces blood loss and post-operative blood transfusion rate largely without major complications . in addition, many meta-analyses have confirmed these results . however, there is little information about comparison among the different routes of txa administration in tka. therefore, this study has been designed to determine which administration route of txa is more effective and safety.

objectives:to assess the efficacy and safety between the two different applying routes. patients in this project will be randomly divided into three groups , one group is a blank group and the rest two receive either the topical or the intravenous form of tranexamic acid during unilateral tka(total knee arthroplasty).the total blood loss(tbl) will be calculated as the primary outcome for efficacy while deep vein thrombosis、pulmonary embolism、acute myocardial infarction 、 acute kidney infarction and cerebral infarction events will be recorded to assess the safety of the tranexamic acid during a six-week follow-up for each patient. all surgery are under general anesthesia, through direct lateral approach with cementless prosthesis.for all patients, the drain tube will be clamped and closed completely for 2 hours; then the clamp will be fully opened.

Eligibility criteria:
inclusion criteria: 1. consented to join in our project. 2. adult patients (greater than 18 years old) 3. patients scheduled for primary unilateral knee arthroplasty exclusion criteria: 1. patients who refuse to sign the inform consent 2. had an allergy to txa. 3. using anticoagulant drugs within a week. 4. coagulopathy (preoperative platelet count \ 1.4, prolonged activated partial thromboplastin time，prothrombin time ，or thrombin time \>1.4 times longer than normal. 5. breastfeeding 6. major comorbidities: severe ischemic heart disease(class iii and iv of new york heart association); sleep apnea syndrome; renal dysfunction ( glomerular filtration rate\ 80 or glutamic oxalacetic transaminase\>80).retinopathy (disturbances of color vision). 9.history of thromboembolic disease

Keywords: tranexamic acid blood loss topical administration intravenous administration